Improving the identification of high-risk non-metastatic castration-resistant prostate cancer patients in clinical practice

Rosinha, A; Rabaça, C; Calais, F; Pinto, JM; Barreira, JV; Fernandes, R; Ramos, R; Fialho, AC; Palma dos Reis, J

http://hdl.handle.net/10400.26/49844

Use this identifier to reference this record.

Name:	Description:	Size:	Format:
Improving the identification of high-risk non-metastatic castration-resistant prostate cancer patients in clinical practice.pdf		1.48 MB	Adobe PDF	Download

Send Feedback

Authors

Abstract(s)

Non-metastatic castration-resistant prostate cancer (nmCRPC) represents a challenging disease state in prostate cancer care. nmCRPC patients with a high risk of progression to metastatic disease who are identified by a prostate-specific antigen doubling time (PSADT) ≤10 months are eligible for treatment with the novel androgen receptor inhibitors (ARIs), shown to delay disease progression and extend survival. However, nmCRPC is often unexploited in clinical practice due to a lack of standardization in the methodology and in the tools used for its identification. In this article, a group of Urology and Oncology specialists with acknowledged expertise in prostate cancer reviews the state of the art in the management of high-risk nmCRPC patients, identifies gaps and unmet needs, and proposes strategies to optimize the identification of this patient subgroup in the clinical practice and improve their health outcomes.